Canaccord Genuity Maintains Buy on Compass Pathways, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 52.2%

Neg 52.2% Neu 0% Pos 0%

Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $20 to $18.